Table 1. Patient and tumour characteristics (N=40).
| Characteristics | |
|---|---|
| Age, Median years (range) | 67 (48-81) |
| N (%) | |
| Gender | |
| Female | 15 (38) |
| Male | 25 (62) |
| Performance status, ECOG | |
| 0 | 4 (10) |
| 1 | 31 (78) |
| 2 | 5 (12) |
| Smoking status | |
| Never | 1 (2) |
| Formera | 28 (70) |
| Current | 11 (28) |
| Stage | |
| III | 3 (7) |
| IV | 37 (93) |
| Histology | |
| Adenocarcinoma | 33 (83) |
| Squamous cell carcinoma | 7 (17) |
| EGFR mutations (only adenocarcinoma patients) | |
| EGFR Wild-type | 33 (100) |
| ALK rearrangements (only adenocarcinoma patients) | |
| ALK wild-type | 22 (67) |
| Not tested | 11 (33) |
| Erlotinib treatment | |
| 1st line | 1 (2) |
| 2nd line | 30 (75) |
| 3rd line | 9 (23) |
| Prior treatment | |
| 1st line | |
| Carboplatin/vinorelbineb | 22 (56) |
| Carboplatin/vinorelbine/bevacizumabc | 17 (44) |
| 2nd line | |
| Pemetrexed | 5 (56) |
| Docetaxel | 4 (44) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group, EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase.
a: Former smoker was defined as having stopped smoking at time of diagnosis.
b: Carboplatin day 1 (AUC 5) and vinorelbine day 1 and day 8 (60-80 mg/m2 (p.o.)) every 3 weeks for a maximum of four cycles.
c: Bevacizumab (7.5 mg/m2 i.v. day 1) was given in combination with chemotherapy. Patients with disease control received subsequent maintenance therapy every 3 weeks until progression or toxicity.